Laurence Klotz, MD, is Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He is also Chairman of the World Urologic Oncology Federation. Additionally, Dr. Klotz is the Founding Editor-in-Chief of the Canadian Journal of Urology.

Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He continued his postgraduate studies with a special fellowship at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology and tumour biology.

Dr. Klotz is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations and committees.

• Medical School, University of Toronto
• Fellow of the American College of Surgeons (FACS)
• Fellow of the Royal College of Surgeons of Canada (FRCSC)
• Member, American Urologic Association (AUA)
• Founder, Prostate Cancer Research Foundation of Canada
• Founding Editor-in-Chief, Canadian Journal of Urology
• President Elect, Canadian Urologic Association (CUA)
• Chairman of World Urologic Oncology Federation (WUOF)
• Editor, Canadian Urologic Association Journal
• Chairman, Canadian Urology Research Consortium
• Chief of Urology, Sunnybrook Health Sciences Centre
• Partner, Can-Am HIFU

Areas of Special Interest: prostate cancer prevention, active surveillance for favorable risk disease, prostate cancer biomarkers and androgen deprivation

Selected Publications:

• Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer


• Active surveillance for early-stage prostate cancer: review of the current literature


• Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts


• Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer


• A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer


• Assessing individual risk for prostate cancer


• PSA recurrence: definitions, PSA kinetics, and identifying patients at risk


• Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer


• Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis


• Androgen replacement and/or 5 alpha reductase inhibitors in aging men


• Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy


• Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines


• The use of genetic markers to determine risk for prostate cancer at prostate biopsy


• Active surveillance for good risk prostate cancer: rationale, method, and results


• Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease


• A systematic review of randomized trials in localized prostate cancer


• Early prostate cancer: prevention, treatment modalities, and quality of life issues


• Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy


• Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial


• Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines


• Controversies in the management of localized prostate cancer: consensus development by Canadian urologists


• Expectant management with selective delayed intervention for favorable-risk prostate cancer


• Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects


• Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients


• Can radiotherapy salvage isolated local recurrence following radical prostatectomy?

In Conferences:

• Session Highlights from the Society of Urologic Oncology 2008 Winter Meeting: Update on Active Surveillance: Mini-symposium on Focal Therapy


• Session Highlights from the American Urological Association 2008 Annual Meeting: PSA Triggers for Intervention During Active Surveillance: Velocity vs. Doubling Time vs. General Linear Mixed Modeling


• Session Highlights from the American Urological Association 2008 Annual Meeting: Prostate Cancer Chemoprevention by a Flavonoid Supplemented Diet in the Transgenic Adenonocarcinoma of the Murine Prostate (TRAMP) Model


• Slide Presentation from the Urological Research Society 2007 Meeting: Comparing PSA Triggers for Treatment for Men with Prostate Cancer on Active Surveillance


• Session Abstract from the Urological Research Society 2007 Meeting: Comparing PSA Triggers for Treatment for Men with Prostate Cancer on Active Surveillance


• Session Highlights from the American Urological Association 2007 Annual Meeting: Prostate Cancer III; With the Evidence Available, What is the Role for Intermittent Androgen Blockade?


• Session Abstract from the American Urological Association 2006 Annual Meeting: Genome-Wide Association Study for Prostate Cancer Using the Affymetrix 10K GeneChip and Evaluation of Susceptibility Genes for Prostate Cancer in a Clinical Setting


• Session Abstract from the American Urological Association 2006 Annual Meeting:A Low-carbohydrate, High-Fat Diet Inhibits Proliferation of Prostate Cancer In Vivo


• Session Highlights from the Society of Urologic Oncology 2005 Meeting: Management of Localized Prostate Cancer